Propranolol for infantile hemangiomas: Promise, peril, pathogenesis

Pediatric Dermatology

Volumn 26, Issue 5, 2009, Pages 642-644

  Frieden, Ilona J ^a   Drolet, Beth A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA 2 ADRENERGIC RECEPTOR; CORTICOSTEROID DERIVATIVE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; GELATINASE A; GELATINASE B; GUANINE NUCLEOTIDE BINDING PROTEIN; PLACEBO; PROPRANOLOL; PROTEIN SUBUNIT; VASCULOTROPIN;

APOPTOSIS; BRADYCARDIA; BRONCHOSPASM; CAPILLARY ENDOTHELIUM; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA POLYMORPHISM; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEMANGIOMA; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INFANT DISEASE; INFANTILE HEMANGIOMA; LETTER; MESENCHYMAL STEM CELL; MOEBIUS SYNDROME; NEUROTOXICITY; OUTPATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SPASTICITY; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME;

ADRENERGIC BETA-ANTAGONISTS; HEMANGIOMA; HUMANS; INFANT; PROPRANOLOL; VASCULAR NEOPLASMS;

EID: 70350028232     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2009.00977.x     Document Type: Letter

References (20)

1. Leaute-Labreze C, Dumas de la Roque E, Hubiche T et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008 358 : 2649 2651.
2. Haggstrom AN, Drolet BA, Baselga E et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007 150 : 291 294.
3. Bennett ML, Fleischer AB Jr., Chamlin SL et al. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol 2001 137 : 1208 1213.
4. Bonifazi E, Colonna V, Mazzotta F et al. Propranolol in rapidly growing hemangiomas. Eur J Pediatr Dermatol 2008 18 : 185 192.
5. Lawley L, Siegfried E. Propranolol treatment for hemangiomas of infancey: risks and recommendations. Pediatr Dermatol 2009 26 : 610 614.
6. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992 326 : 1456 1463.
7. Barlow CF, Priebe CJ, Mulliken JB et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998 132 : 527 530.
8. Buchhorn R, Hulpke-Wette M, Hilgers R et al. Propranolol treatment of congestive heart failure in infants with congenital heart disease: The CHF-PRO-INFANT Trial. Congestive heart failure in infants treated with propanol. Int J Cardiol 2001 79 : 167 173.
9. Buchhorn R, Hulpke-Wette M, Nothroff J et al. Heart rate variability in infants with heart failure due to congenital heart disease: reversal of depressed heart rate variability by propranolol. Med Sci Monit 2002 8 : CR661 CR666.
10. Drago F, Mazza A, Guccione P et al. Amiodarone used alone or in combination with propranolol: a very effective therapy for tachyarrhythmias in infants and children. Pediatr Cardiol 1998 19 : 445 449.
11. Friedman AL, Hustead VA. Hypertension in babies following discharge from a neonatal intensive care unit. A 3-year follow-up. Pediatr Nephrol 1987 1 : 30 34.
12. Gillette P, Garson A Jr., Eterovic E et al. Oral propranolol treatment in infants and children. J Pediatr 1978 92 : 141 144.
13. Smith C, Thomsett M, Choong C et al. Congenital thyrotoxicosis in premature infants. Clin Endocrinol (Oxf) 2001 54 : 371 376.
14. Villain E, Denjoy I, Lupoglazoff JM et al. Low incidence of cardiac events with beta-blocking therapy in children with long QT syndrome. Eur Heart J 2004 25 : 1405 1411.
15. DeGeorge BR Jr., Koch WJ. Beta blocker specificity: a building block toward personalized medicine. J Clin Invest 2007 117 : 86 89.
16. Takahata Y, Takarada T, Iemata M et al. Functional expression of beta2 adrenergic receptors responsible for protection against oxidative stress through promotion of glutathione synthesis after Nrf2 upregulation in undifferentiated mesenchymal C3H10T1/2 stem cells. J Cell Physiol 2009 218 : 268 275.
17. Annabi B, Lachambre MP, Plouffe K et al. Propranolol adrenergic blockage inihibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 2009 Epub. ahead of print J. Progenitor cells in infantile hemangioma. J Craniofac Surg 2009 20 (Suppl 1 695 697.
18. Boye E, Jinnin M, Olsen BR. Infantile hemangioma: challenges, new insights, and therapeutic promise. J Craniofac Surg 2009 20 (Suppl 1 678 684.
19. Drolet BA, Swanson EA, Frieden IJ. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr 2008 153 : 712 715, 715 e711.
20. Liggett SB, Cresci S, Kelly RJ et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008 14 : 510 517.